SCHEMBL20580338

SCHEMBL20580338

NC1CN(c2cc(F)c(F)c(F)c2)c2ccccc2NC1=O

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
BRD4 O60885 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
EGFR P00533 1/20 0.32
AADAT Q8N5Z0 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
IDO1 P14902 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20580336 1.00 ALDH1A1 (0.37) ALDH1A1KDM4EGAAMAPTHTT
SCHEMBL15628080 0.84 MAPT (0.39) ALDH1A1KDM4EGAAMAPTADORA3
SCHEMBL20580064 0.84 GAA (0.42) ALDH1A1KDM4EGAAMAPTHTT
SCHEMBL7657163 0.84 GAA (0.42) ALDH1A1KDM4EGAAMAPTHTT
SCHEMBL7657174 0.84 GAA (0.42) ALDH1A1KDM4EGAAMAPTHTT
Bromide SCHEMBL6178391 0.82 GAA (0.41) ALDH1A1KDM4EGAAMAPTHTT
SCHEMBL15628126 0.80 HTR7 (0.40) ALDH1A1KDM4EGAAMAPTMEN1
SCHEMBL15628122 0.79 MEN1 (0.40) ALDH1A1KDM4EGAAMAPTMEN1
SCHEMBL15628087 0.77 DPP4 (0.39) KDM4EGAAMAPTIDO1
SCHEMBL15628123 0.77 HTR6 (0.45) ALDH1A1KDM4EGAAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752598-B2 Aryldiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-08-25 US disclosed
WO-2018226801-A1 ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2018-12-13 WO disclosed
US-20180354912-A1 ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2018-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180354912-A1 ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS AHR, FURIN, CYP3A5 ALDH1A1 375/4885KDM4E 544/4885GAA 1415/4885
US-10752598-B2 Aryldiazepine derivatives as RSV inhibitors AHR, FURIN, CYP3A5 ALDH1A1 375/4885KDM4E 544/4885GAA 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.